Btg Share Discussion Threads

[steeplejack] 17/5/2016 08:20

There are,of course,some encouraging things in these results.Revenue growth exceeding top end forecasts,steady profit margins etc.

[pawdaw] 17/5/2016 07:56

"Approximately 161 million US lives (of 320 million total US insured lives) are now covered by payers who have Varithena(R) on policy, with approximately 91 million lives covered by insurers who have also paid claims at appropriate rates. Further progress is anticipated during the current financial year.

...We look forward to launching Varithena(R) in Canada during 2017 ..."

May as well get all the bad news out of the way in one go, Bargainbob.

[fhmktg] 06/5/2016 16:51

Well, that cheered me up for the weekend!

[muffmitz] 06/5/2016 15:36

I am today calling the bottom on BTG (+ or - 5%) at 5.74.

The reasons why? One important factor is that the Sun rose in the East this morning. The second reason is that 19 out of twenty city gurus and 3 out of 20 experts on this thread predicted that the Sun would set in the West. And don't forget, Varithena has 9 letters which is the number of players Tottenham should have had on the field at the end of their last 'match'. Combined with the fact that today is May 6 the portents are extremely compelling.

Fill your boots. It'll be your last chance!

[fhmktg] 06/5/2016 14:28

You and me together, Bill; it's been a while since Runcorn Heath developed the anti-venom.I just hope that there is more than 'still waiting' when the Varithena update comes.Top line growth is very impressive and a doubling of sales over the next couple of years doesn't seem beyond the realms of the possible.

[bill hunt] 06/5/2016 13:55

Each acquisition so far has proved to be a potential or already earnings enhancing. Quite impressed with the progress since joining with Protherics. Share price was frothy for a short period but the company have never promised jam today and have always projected into 2021. Just hope that I am around to see it. If uncertain then do not gamble.

[fhmktg] 06/5/2016 12:17

The Dame is building up a VERY attractive portfolio of businesses!

[semper vigilans] 06/5/2016 11:41

They better be good ones.

[revoman] 06/5/2016 11:37

It's all about prospects.

[waterloo01] 06/5/2016 11:26

Minor deal but very expensive. $85m (plus $25m on approvals). Company turnover $22m, gross assets of $14m and $8.5m loss.

[revoman] 06/5/2016 11:05

Nice bolt-on today, funded by internal cash resources.

[alanrussell] 05/5/2016 00:17

Weak dollar isn't helping.

[fhmktg] 04/5/2016 23:37

I feel better already!Thanks

[charlock] 04/5/2016 17:45

Tuesday May 17th...

[fhmktg] 04/5/2016 16:09

Healthcare sector out of favour at the moment.Results plus forward view on 15th May might just give some optimism.

[amaretto1] 30/4/2016 18:28

No matter how u look at it, BTG is a poor performer/investment.

The chart says it needs to hold......i mean the spread bet companys !!

[bargainbob] 30/4/2016 08:47

Abbott Laboratories, the US pharmaceutical, has agreed to acquire St Jude Medical for an equity value of about $25bn, the first major healthcare deal after a three month slowdown in the merger and acquisition activity that characterized the industry last year.

The Illinois-based company will give St Jude’s shareholders $46.75 in cash and 0.8708 shares of Abbott stock, valuing the medical devices company at about $85 per share. The offer represents a 37 per cent premium on St Jude’s closing share in Wednesday at $61.97, writes James Fontanella-Khan, US M&A correspondent.

The Financial Times first reported that Abbott was preparing a bid $25bn bid for St Jude in August last year, however, at the time the company denied that it was planning a takeover of the medical devices group.

Abbott’s acquisition of St Jude could spark a fresh wave of healthcare M&A, with a particular focus in the medical devices and technology focused medical equipment.

In a release, Abbott said the acquisition will bolster its strategic and competitive positions in the cardiovascular segment, boost is business across new geographies and will generate pre-tax synergies worth $200m a year annually by 2020.

Miles White, chairman and chief executive officer of Abbott said:

Bringing together these two great companies will create a premier medical device business and immediately advance Abbott’s strategic and competitive position.

The combined business will have a powerful pipeline ready to deliver next-generation medical technologies and offer improved efficiencies for health care systems around the world.

[jadeticl3] 30/4/2016 07:57

Spyder, what was that news about St Jude,,please?

[spyder] 29/4/2016 19:21

Hi amaretto1 - I am sorry this share is causing you such anxiety, it has certainly been a frustrating hold over the last few weeks/months. I fear that we will see further weakness in the short term as a key support gave way today, it needs to bounce from here otherwise all short term holders should get out quick.
I had wondered whether the news about St Jude over night might provide a bit of support today, but no such luck. In a rational world it probably should have done.
I am still a committed long term holder.

[ch1ck] 23/4/2016 07:41

The fundamentals and prospect for the share remain good with a strong pipeline of products. The fact the share is in decline to me seems to be a natural roll over from the recent climb out and the share has yet to form a positive up trend.Until we see this the majority of investors will stay clear. Although Invested here I wait to see a large up tick in volume or a big move in pharma stocks before committing any real money.Happy to hold